2.1
Obecabtagene autoleucel (obe‑cel; Aucatzyl, Autolus Limited) is indicated for 'the treatment of adult patients (≥ 18 years) with relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia'.
2 Information about obecabtagene autoleucel
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for obe-cel.
Price
2.3
The list price for obe‑cel is £372,000 per infusion (company submission).
2.4
The company has a commercial arrangement. This makes obe‑cel available to the NHS with a discount. The size of the discount is commercial in confidence.